Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

T cell subsets, NK cells and natural killer T cells (NKT) showed a trend for reduction, although not significant (CD3 + CD4 + T cells: 0.39 ± 0.05 vs. 1.67 ± 0.15 * 10 2 cells/μl; CD3 + CD8 + T cells: 0.16 ± 0.03 vs. 1.03 ± 0.12 * 10 2 cells/μl; NK cells: 0.15 ± 0.03 vs. 1.00 ± 0.25 * 10 2 cells/μl; NKT cells: 0.02 ± 0.01 vs. 0.11 ± 0.03 * 10 2 cells/μl; for all cell subsets p > 0.05).
Correlation of DTI metrics and cognitive output Low diffusivities showed a trend towards higher cognitive scores in many ROIs but in most cases, it did not reach statistical significance after correction of the p -value for multiple comparisons.
The RMSD of the compound relative to 3-C like protease maintained an increasing trend in the first 25 ns or so, and showed a trend of decreasing and then increasing to the RMSD value at 25 ns from 25 to 40 ns, and basically maintained equilibrium with less fluctuation in the last 10 ns.
73 Interestingly, 7 R/R patients received the triplet ENA+AZA+Ven and showed a trend toward a better mOS than those treated with ENA+AZA. 73 Preliminary results of a phase Ib/II clinical trial (Enaven-AML trial) explored enasidenib in combination with VEN in a group of AML patients previously treated with at least two lines of treatment and mostly with relapsing or refractory disease. 74 A CR rate of 55% was observed, and all responders remained in remission during the study. 74 Since IDH mutations induced inhibition of the TET2 enzyme, it seemed interesting to explore the effect of VEN-based therapies in TET2 -mutated AMLs.
1 Indeed, the PARAGON-HF study recently showed a trend towards better clinical outcome in chronic renal failure patients treated with sacubitril/valsartan than valsartan itself, especially in the lower end of the EF spectrum, in women, in patients recently hospitalized for heart failure and in those with high sensitivity troponin values at baseline.